T 0689/19 (Dasatinib in the treatment of chronic myelogenous leukemia/BRISTOL) of 04.10.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T068919.20211004
- Date of decision
- 4 October 2021
- Case number
- T 0689/19
- Petition for review of
- -
- Application number
- 04758053.5
- IPC class
- A61K 31/427A61K 31/506A61P 35/02
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
- Applicant name
- Bristol-Myers Squibb Holdings Ireland
- Opponent name
- Sandoz Farmacêutica Lda.
Mylan, LDA
Zentiva k.s. - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 105(1)(a)European Patent Convention Art 111(2)European Patent Convention Art 56
- Keywords
- Intervention of the assumed infringer - admissible (yes)
Res judicata - decision on sufficiency binding
Inventive step - (yes) - Catchword
- -
- Cited cases
- G 0004/91G 0010/91G 0001/94G 0001/97G 0001/03G 0003/04G 0002/19R 0001/08T 0021/89T 0079/89T 0843/91T 0934/91T 1063/92T 0153/93T 0167/93T 0460/95T 0863/96T 0598/98T 0817/00T 0694/01T 1018/03T 1459/06T 0898/07T 1545/08T 0584/09T 0223/11T 1713/11T 0950/13T 0308/14T 0488/16T 0439/17
- Citing cases
- T 2194/22
Order
For these reasons it is decided that:
The appeals are dismissed.